Background
The primary goal of this guideline was to develop evidence-based recommendations for the testing of immunotherapy biomarkers including program death ligand-1 (PD-L1) and tumor mutation burden (TMB) in patients with advanced non-small cell lung cancer.
Six evidence-based recommendations for PD-L1 and TMB testing in the clinical setting are published in the “PD-L1 and TMB Testing of Patients with Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation” as an early online release by the Archives of Pathology & Laboratory Medicine.
Pathologists, clinicians, laboratory personnel, and quality managers are encouraged to implement the guideline using the CAP tools and resources found below.
Guideline Information
- Status: Active
- Guideline published online ahead of print: April 16, 2024
- Originally published: July 2024
- Collaborators: Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, LUNGevity Foundation
Guideline Tools and Resources
Download the following materials to help implement the guideline: